These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26975633)

  • 21. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
    Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
    Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
    Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
    Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
    Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p38 MAPK inhibitor SB203580 enhances anticancer activity of PARP inhibitor olaparib in a synergistic way on non-small cell lung carcinoma A549 cells.
    Dey P; Biswas S; Das R; Chatterjee S; Ghosh U
    Biochem Biophys Res Commun; 2023 Aug; 670():55-62. PubMed ID: 37276791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
    Guo ZP; Hu YC; Xie Y; Jin F; Song ZQ; Liu XD; Ma T; Zhou PK
    Biochem Biophys Res Commun; 2017 Jan; 483(1):223-229. PubMed ID: 28034751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
    J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
    Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
    Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
    Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
    Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
    Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 33. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
    Zhao Y; Zhou K; Xia X; Guo Y; Tao L
    Cell Cycle; 2023 Jan; 22(2):200-212. PubMed ID: 35959961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.
    Chen S; Wang G; Niu X; Zhao J; Tan W; Wang H; Zhao L; Ge Y
    Cancer Lett; 2014 Jun; 348(1-2):20-8. PubMed ID: 24534203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
    Engert F; Schneider C; Weiβ LM; Probst M; Fulda S
    Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
    Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ
    Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 40. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
    Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.